Vimarsana
Biggest News Aggregation in the World

Safety Summary News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safety Summary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safety Summary Today - Breaking & Trending Today

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery - Vimarsana News

REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

Published: November 3, 2023

ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoSteve PakolaPeter KaiserChris BrinzeyDana CormackMark BarakatAmerican Academy Of OphthalmologyTechnology PlatformExchange CommissionCole Eye InstituteCorporate CommunicationsTechnology Platform LicenseesClearside Biomedical IncOphthalmology ResearchSecurities ExchangeCleveland Clinic Lerner College Of MedicineDiabetic Retinopathy Severity ScaleAmerican AcademyRetinal ConsultantsChief Medical OfficerSafety SummaryCorrected Visual AcuityChaney Family Endowed ChairCleveland Clinic Lerner College
Adverum Biotechnologies Announces Positive Aflibercept - Vimarsana News

Adverum Biotechnologies Announces Positive Aflibercept

Published: September 26, 2023

- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically...

Source: globenewswire.com
Related Topics:
United StatesUnited KingdomLaurent FischerArshadm KhananiAmerican Academy OphthalmologyHealthcare Products Regulatory AgencyExchange CommissionAdverum Biotechnologies IncEuropean Medicines AgencyDrug AdministrationSierra Eye AssociatesClinical Program MilestonesScientific Advisory BoardAflibercept Protein Level Data HighlightsKey Baseline CharacteristicsAflibercept Protein Expression LevelsSafety SummaryFast TrackInnovation PassportPrivate Securities Litigation Reform ActQuarterly ReportNasdaq AdvmAdverum BiotechnologiesGene TherapyWet Macular Degeneration